Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls

• Urvi A. Shah,
• Sæmundur Rögnvaldsson,
• Andriy Derkach,
• Magnus Björkholm,
• Ingemar Turesson,
• Yael David,
• Malin Hultcrantz,
• Carlyn Tan,
• Hani Hassoun,
• Neha Korde,
• Alexander Lesokhin,
• Sham Mailankody,
• Sigurður Yngvi Kristinsson,
• C. Ola Landgren

Affiliations

Urvi A. Shah

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Sæmundur Rögnvaldsson

Department of Medicine, University of Iceland

Andriy Derkach

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York

Magnus Björkholm

Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm

Ingemar Turesson

Department of Hematology, Skane University Hospital Malmö/Lund

Yael David

Department of Chemical Biology, Sloan Kettering Institute, New York

Malin Hultcrantz

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Carlyn Tan

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Hani Hassoun

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Neha Korde

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Alexander Lesokhin

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Sham Mailankody

Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

Sigurður Yngvi Kristinsson

Department of Medicine, University of Iceland, Iceland; Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm

C. Ola Landgren

Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami